Which companies are Evopoint Biosciences's closest peers?

The cockpit's peer set: Arcus Biosciences (RCUS), Palvella Therapeutics (PVLA), Xencor (XNCR), Hebei Changshan Biochemical Pharmaceutical (300255.SZ), MBX Biosciences (MBX), Walvax Biotechnology (300142.SZ), Beam Therapeutics (BEAM), Pharvaris (PHVS).

Is Evopoint Biosciences expensive compared with its peers?

On ev / sales it trades at 67.9× against a peer median of 9.5×, 2nd most expensive of 17 in its peer set.

← CockpitCompetitor Analysis › 688837.SS Evopoint Biosciences Co LtdOpen in the cockpit ↗

Evopoint Biosciences Co Ltd688837.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$2.58B

US dollars, full cap

Free float

100%

of shares outstanding

$/day

$42.6M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 17.5%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥39.50

1D-2.5%

1W+17.0%

1M-20.4%

3Mn/a

6Mn/a

YTDn/a

1Yn/a

ATR %11.5%

52w lowhigh50.0% off high

What Evopoint Biosciences does

Employees: 362

Evopoint Biosciences at a glance

Size Evopoint Biosciences (688837.SS) is a China Health Care company (Biotechnology) with a market value of $2.58B, the 1005th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥39.50 on 6 Nov 2026.

Valuation It trades at 67.9× enterprise value to sales against a peer median of 9.5× (2nd most expensive of 17).

Evopoint Biosciences financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023
Revenue	CN¥235M	CN¥935M	CN¥0	CN¥0
Revenue growth	—	—	—	—
Gross profit	n/a	n/a	-CN¥30.8M	-CN¥23.3M
EBITDA	n/a	CN¥254M	-CN¥432M	-CN¥427M
Net income	-CN¥453M	CN¥203M	-CN¥386M	-CN¥427M
Free cash flow	n/a	CN¥119M	-CN¥386M	-CN¥455M
Capital expenditure	n/a	CN¥62.6M	CN¥50.1M	CN¥90.1M
Total debt	CN¥1.32B	CN¥898M	CN¥521M	CN¥412M

Quarterly statements and history in the cockpit →

Evopoint Biosciences competitors and peer comparison

How Evopoint Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Evopoint Biosciences against its 20 peers (data as of 6 Nov 2026)
Measure	688837.SS	Peer median	Rank in peer set
1-month return	-20.4%	+3.4%	2nd lowest of 21
Distance from 52-week high	-50.0%	-27.1%	3rd lowest of 21
EV / Sales	67.9×	9.5×	2nd most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Evopoint Biosciences 688837.SS	China	$2.58B	n/a	n/a	n/a	67.9×	n/a	n/a
Arcus Biosciences RCUS	United States	$2.59B	-28%	-55%	-415%	17.1×	n/a	n/a
Palvella Therapeutics PVLA	United States	$2.53B	+45%	-100%	n/a	n/a	n/a	n/a
Xencor XNCR	United States	$2.66B	+178%	-29%	-206%	22.6×	n/a	n/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZ	China	$2.68B	-52%	0%	-25%	21.9×	n/a	n/a
MBX Biosciences MBX	United States	$2.47B	+25%	n/a	n/a	n/a	n/a	n/a
Walvax Biotechnology 300142.SZ	China	$2.71B	-12%	-23%	5%	10.3×	31.3%	-3.8%
Beam Therapeutics BEAM	United States	$2.73B	-18%	+163%	-268%	13.2×	n/a	n/a
Pharvaris PHVS	United States	$2.41B	+14%	n/a	n/a	n/a	n/a	n/a
Xiamen Amoytop Biotech 688278.SS	China	$2.76B	-23%	+18%	27%	4.7×	0.5%	+36.0%
Xeris Biopharma XERS	United States	$2.77B	+133%	+36%	11%	8.8×	33.3%	+70.2%
BGI Genomics 300676.SZ	China	$2.39B	-4%	0%	-14%	3.7×	n/a	n/a
Celldex Therapeutics CLDX	United States	$2.35B	-12%	-97%	-206,220%	10,375.3×	n/a	n/a
ADMA Biologics ADMA	United States	$2.85B	+56%	+8%	42%	5.7×	-0.8%	+64.6%
Sunshine Lake Pharma 6887.HK	Hong Kong	$2.85B	-9%	+20%	-3%	6.1×	n/a	n/a
Zealand Pharma A/S ZEAL.CO	Denmark	$2.32B	-32%	-49%	51%	0.3×	n/a	n/a
Hemab Therapeutics COAG	United States	$2.29B	+95%	n/a	n/a	n/a	n/a	n/a
Rubicon Research RUBICON.NS	India	$2.91B	+74%	+37%	21%	14.2×	n/a	n/a
Septerna SEPN	United States	$2.28B	+105%	+13,520%	-57%	19.5×	18.7%	n/a
Zai Lab 9688.HK	Hong Kong	$2.92B	+13%	+5%	-59%	5.5×	n/a	n/a
Bavarian Nordic A/S BAVA.CO	Denmark	$2.93B	+27%	-3%	16%	2.8×	-2.0%	+27.4%

Questions

Which companies are Evopoint Biosciences's closest peers?: The cockpit's peer set: Arcus Biosciences (RCUS), Palvella Therapeutics (PVLA), Xencor (XNCR), Hebei Changshan Biochemical Pharmaceutical (300255.SZ), MBX Biosciences (MBX), Walvax Biotechnology (300142.SZ), Beam Therapeutics (BEAM), Pharvaris (PHVS).
Is Evopoint Biosciences expensive compared with its peers?: On ev / sales it trades at 67.9× against a peer median of 9.5×, 2nd most expensive of 17 in its peer set.